Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Biomarcatori microbici metabolomici e intestinali del trattamento della cessazione del fumo nella terapia farmacologica a lungo termine: uno studio controllato randomizzato

28 settembre 2026 aggiornato da: Sigmund Freud PrivatUniversitat

Theoretical Framework: Cigarette smoking is the leading preventable cause of death worldwide, with nicotine dependence notably common among individuals with Substance Use Disorders (SUD). Smoking exacerbates both physical and mental health issues, further complicating the treatment of SUD. Current therapeutic approaches for SUD often prove inadequate, indicating a need for new strategies. Recent advancements in metabolomics and gut microbiome research have provided valuable insights into the biological mechanisms underlying addiction.

Objectives: This study aims to investigate the therapeutic potential of smoking cessation for individuals with SUD, using a six-week intervention within a therapeutic community. The research specifically explores the psychobehavioral, metabolic, and gut microbiome domains. It is hypothesized that smoking cessation will improve emotional regulation, self-efficacy, and reduce substance craving, mediated by changes in metabolic and microbiome profiles linked to brain reward systems.

Methods: A randomized controlled trial (N=150) will be conducted, examining outcomes such as clinical relapse rates, microbial and metabolic markers, particularly in choline and folate metabolism. Participants with SUD (n=100) will undergo a six-week smoking cessation intervention, with pre- and post-assessments, compared to a control group receiving treatment as usual. Metabolomic and microbiome analyses will be conducted using blood and stool samples, alongside psychological assessments via questionnaires. Assessments on a behavioural level will take place at a 3-months follow-up.

A cross-sectional, non-interventional healthy control group (n=50) will be examined at a single timepoint with an anologous panel of psychological variables, blood and stool to ascertain differences between smokers with SUD and healthy controls.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

97

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Fehring, Austria, 8350
        • Grüner Kreis Organization Johnsdorf Facility
      • Graz, Austria, 8036
        • Medical University Graz
      • Vienna, Austria, 1020
        • Sigmund Freud Private University Vienna

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • diagnosis of a form of substance use disorder (F1x.x) by a licensed psychiatrist according to ICD-10
  • minimum age of 18 years
  • sufficient knowledge of the German language
  • willingness to quit smoking
  • willingness and ability to consent

Inclusion criteria for healthy controls :

  • minimum age of 18 years
  • sufficient knowledge of the German language
  • willingness and ability to consent

Exclusion Criteria:

  • lack of consent, inability to provide informed consent
  • age below 18,
  • acute psychotic symptoms or acute suicidal tendencies
  • cardiovascular disease
  • pregnancy or breastfeeding
  • severe mental or organic illnesses (such as epilepsy, brain tumors, recent major surgery), tumor diseases, dementia (Mini Mental Score <20), severe autoimmune diseases or immunosuppression, acute infections, or acute diarrhea, prior gastrointestinal surgery (except appendectomy)
  • probiotic intake within the last 6 months,
  • ongoing consumtion of dietary supplements, probiotics, antibiotics, or prebiotic supplements during the study
  • prior participation in a smoking cessation programme

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Treatment As Usual

Patients in the TAU group receive long-term rehabilitation drug treatment according to the 'community as a treatment'-model

The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.

Sperimentale: 6-weeks smoking cessation cognitive-behavioral therapy intervention

The "smoke free in 6 weeks" program is a standardized behavioural therapy intervention that takes place once a week for 1.5 hours over 6 weeks and is provided by the Austrian health insurance provider Österreichische Gesundheitskasse (ÖGK).

The standard treatment within the 'Grüner Kreis' therapeutic community - which all participants will receive - consists of group therapy (once a week), individual psychotherapy (once a week), counselling by social workers, psychiatric consultations, as well as sport-, art- and work-therapy. Daily life is organized according to principles of therapeutic community-based addiction treatment.

Held in the therapeutic community, the intervention will employ principles of cognitive-behavioural therapy (CBT) coupled with personalized recommendations for nicotine replacement. The Austrian Health Insurance standard for therapy will be guiding the program's content, which is tailored for inpatient clients. Specifically, the following interventions based on CBT techniques will be applied in the weekly group sessions consisting of 10 to 15 participants: Psychoeducation including information on tobacco addiction, health risks, advice on relapse prevention and the handling of craving, motivation building, behavioural observation.

Nessun intervento: Healthy controls

Control group with n=50 healthy adult subjects, examined at a single timepoint. No interventions will be administered in this arm.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Self-efficacy
Lasso di tempo: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period

Self-efficacy as a psychological variable and will be assessed by the Self-Efficacy Scale (SWE), a self-report instrument for measuring general optimistic self-confidence. It consists of 10 items and measures optimistic competence expectancy, i.e., confidence in solving difficult situations with one's own abilities.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period
General substance-related craving
Lasso di tempo: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Substance related craving will be assessed by the MaCS (Mannheim Craving Scale). consists of 12 items and four additional items and is rated on a 5- point Likert scale.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Tobacco dependence
Lasso di tempo: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Tobacco dependence will be assessed by The Fagerström Test for Cigarette Dependence (formerly Fagerström Test for Nicotine Dependence; FTND). It consists of 6 categorically scaled items that assess the number of smoked cigarettes per day (CPD), compulsive use, and dependence intensity.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Primary Affects
Lasso di tempo: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Primary Affects, as proposed by Jaak Panksepp will be assessed by the German Version of the Brief Affective Neuroscience Personality Scales including a LUST Scale (BANPS-GL), a self-report questionnaire.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.
Metabolome
Lasso di tempo: From enrollment to the end of the 6-weeks treatment period.

Metabolome will be ascertained from blood via state-of-the-art NMR (nuclear magnetic resonance).

From enrollment to the end of the 6-weeks treatment period.
Gut microbiome
Lasso di tempo: From enrollment to the end of the 6-weeks treatment period.

Gut microbiome will be ascertained via 16s-rRNA sequencing from stool.

From enrollment to the end of the 6-weeks treatment period.
Smoking behaviour
Lasso di tempo: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Participants will be asked regarding their daily smoked cigarettes in the last two weeks (interval scaled). A second single item question will be, if participants have been completely abstinent from tobacco smoking in the last two weeks (dichotome).

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Psychiatric Symptoms
Lasso di tempo: From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

For the evaluation of psychopathology, the ICD-10 Symptom Rating (ISR) questionnaire will be utilized. In accordance with the ICD-10, this self-assessment questionnaire, comprising 30 items, is designed to comprehensively assess the status and severity of mental disturbances. Symptoms of the six symptomatic patterns - depressive, anxiety, obsessive-compulsive, eating disorders, somatoform syndrome, and post-traumatic stress disorder - are assessed.

From enrollment to follow-up 3 months after the end of the 6-weeks treatment period.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

5 maggio 2025

Completamento primario (Effettivo)

18 settembre 2026

Completamento dello studio (Effettivo)

18 settembre 2026

Date di iscrizione allo studio

Primo inviato

23 gennaio 2025

Primo inviato che soddisfa i criteri di controllo qualità

27 gennaio 2025

Primo Inserito (Effettivo)

31 gennaio 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 settembre 2026

Ultimo verificato

1 marzo 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 1155/2024
  • 1155/2024 (Altro identificatore: Ethikkommission der Medizinischen Universität Graz)

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi